Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2003-132 – Mayo Clinic has patent rights claiming methods of detecting the autoantibody associated with NMO.
2012-112 – We have identified abnormalities in the B cell compartment in the circulation of patients with ALS. This abnormality could be used to develop a test to measure the prognosis of patients with ALS or to diagnose patients with different forms of the disease. Additionally, the involvement of B cells in the pathology of ALS will lead treatments that may ameliorate the disease or its symptoms.
Nuclear Reprogramming Through Oxygen-Independent Metabotype Purges Dysfunctional Mitochondrial Heteroplasmy
2012-007 – Mitochondrial disease is inherited through maternal transmission of mutated mitochondrial DNA (mtDNA) with disease phenotypes determined by the unpredictable mixture of mutant and wild-type mtDNA. Mitochondrial heteroplasmy is dependent upon stochastic segregation of mtDNA into discrete units during early embryogenesis as mtDNA replication is shut off during blastomere expansion. Since... Read More
Mutations in the KCND3-Encoded Kv4.3 Potassium Ion Channel and Use in Diagnostic Methodologies for the Detection of Sudden Death-Predisposing Cardiac Channelopathies
2011-122 – The present invention details mutations in the KCND3-encoded Kv4.3 potassium ion channel that are associated with sudden death predisposing genetic conditions such as Brugada syndrome (BrS) and long QT syndrome (LQTS) and the mechanism by which at risk individuals can be screend for potentially life threatening mutation isn this gene. This invention is based on the that mutations within the... Read More
2007-012 – Technology Description The past 20 years have witnessed an unprecedented increase in eosinophil-associated diseases such as allergy, asthma, and inflammatory gastrointestinal syndromes. Despite this rise in the need for an eosinophil-specific assay few reagents are available. Mayo Clinic researchers have developed a unique monoclonal antibody reactive to the eosinophil specific protein... Read More
2006-295 – Tandem Biomarkers Identifies a Unique Population of Cardiopoietic Stem Cells Biomarkers used to purify a cardiac-specific stem cell population have not previously been reported. This invention reports the discovery of 1) the first cell surface tag that identifies cardiac progenitors from stem cell population and 2) an efficient approach to enrich large quantities of cardiac progenitors for... Read More
Genetic Polymorphisms in the Human Cytochrome P450, Family 19, Subfamily A, Polypeptide 1 (CYP19A1) gene in Caucasian, African American, Han Chinese and Mexican American Populations
2005-156 – Some of the known substrates of CYP19A1 (aromatase) include testosterone and androstenedione. It is expressed in the ovaries, testes, placenta, fetal liver, adipose tissue, chondrocytes, osteoblasts, vasculature smooth muscle, and brain. Increased or decreased enzyme activity is associated with several diseases including breast and endometrial cancer. Several novel polymorphisms have been... Read More
2005-124 – Common, functionally relevant mutations in the SULT1A1 have been recently discovered. These mutations have a significant effect on SULT1A1 enzyme activity.
2004-291 – Technology Description Pathogenic mutations of the Leucine-Rich Repeat Kinase 2 (LRRK2) enzyme are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism. Mayo Clinic researchers were the first to identify this association and have gone on to develop an in-depth understanding of LRRK2 function as well as numerous tools to help identify therapeutic agents to... Read More
Genetic Polymorphisms in the Human Hydroxy-delta-5-steroid Dehydrogenase, 3 Beta-and steroid delta-isomerase 1 (HSD3B1) gene in Caucasian, African American, Han Chinese and Mexican American populations
2004-274 – Substrates include pregnenolone, 17-hydroxypregnenolone (17-OH-Preg), dehydroepiandrosterone (DHEA) and androst-5-ene-3-B,17B-diol. Tissue specificity includes the placenta and skin but it is predominantly expressed in mammary gland tissue. Subcellularly, it is located in the endoplasmic reticulum and the mitochondrial membrane. Congenital deficiency of 3 beta HSD activity causes severe... Read More
Genetic Polymorphisms in the Human Glutathione S-transferase Omega 2 (GSTO2) Gene in Caucasian, African American, Han Chinese and Mexican American Populations
2004-273 – GST02 is a phase II enzyme that utilize glutathione in reactions contributing to the transformation of a wide range of exogenous and endogenous compounds, including carcinogens, therapeutic drugs, and products of oxidative stress. Known substrates are glutathione (GSH) and dehydroascorbate (DHA. It is expressed in liver, kidney and skeletal muscle and at high levels in the testes and low... Read More
2003-149 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2002-152 – PNMT is the terminal enzyme in catecholamine biosynthesis and catalyses the synthesis of epinephrine from norepinephrine. Norepinephrine and Phenylethanolamine are substrates. The activation is methylation. It is expressed in Chromaffin cells of the Adrenal Medulla, medulla oblongata, hypothalamus, and sensory nuclei of the vagus nerve. Diseases and conditions that may be associated with... Read More
2002-151 – SULT1A3 is involved in the sulfation of Dopamine,other catechol monoamines, serotonin, and Troglitazone. It is expressed in liver, brain, jejunum, kidney and platelets. It may be associated with schizophrenia, affective disorders, renal disease and chemical carcinogenesis. One particular polymorphism, resulting in an amino acid change, was found to be present in 4% of the African American... Read More
2002-126 – The activity of the gene product is Sulfate conjugation. Several non-synonymous CSNPs have been discovered that affect the enzyme activity.
2001-139 – There are two separate 3'-phosphoadenosine 5'-phosphosulfate synthetase (PAPSS) isoforms in humans (PAPSS1 and PAPSS2). Both isoforms catalyze the formation of PAPS, the universal high-energy sulfate donor for all sulfotransferases. Functionally relevant PAPSS1 polymorphisms have been discovered that decrease PAPSS1 activity and result in undersulfation of drugs, procarcinogens, glycoproteins... Read More
2001-138 – SULT1E1 catalyzes reactions with steroid hormones e.g. ß-Estradiol, by transferring a sulfonate group from PAPS to the hydroxy group at position 3 of the estrogen to form Estradiol 3-O-sulfate. Known substrates are estrone and estradiol, catecholestrogens and 2-Methoxyestradiol. SULT1E1 is expressed in the liver, small intestine, adrenal cortex, adrenal medulla, lung, kidney, mammary gland,... Read More
2001-009 – SULT2A1 catalyzes the transfer of inorganic sulfate to hydroxysteroids and uses PAPS as the sulfate donor. Genetically based variations in SULT2A1 may affect the metabolism of steroid compounds (DHEA, ethinyl estradiol, minoxidil, androsterone, androstenediol, epiandrosterone, androgens, estrogens, testosterone, and pregnenolone) that are used for drugs, as well as structurally related... Read More
2000-100 – PAPSS2 is an enzyme that synthesizes PAPS; the high-energy sulfate donor molecule involved in the sulfate conjugation (metabolism) of thousands of drugs, hormones (estrogen), neurotransmitters (dopamine) and many other macromolecules. Rare inactivating mutations in orthologous PAPSS2 genes have been identified as the genetic causes for human spondyloepimetaphyseal dysplasia and murine... Read More
2000-031 – Human SULT1C1 has been shown to metabolically activate planar phenols and the chemical procarcinogen N-OH-2-acetylaminoflurorene. Therefore, genetically based variations in the activity of this enzyme may affect the activation of procarcinogens. In addition, SULT1C1 polymorphisms may play a role in thyroid hormone inactivation since this enzyme metabolizes thyroid hormones. Therefore,... Read More
1998-071 – Substrates for SULT1A1 are; 4-nitrophenol, 17beta-estradiol (E2), diethylstilboestrol (DES), 1-naphol, 4-hydroxytamoxifen, minoxidil, estrone (E1), epinephrine, dopamine, acetaminophen, genistein, other monocyclic phenols. The gene is ubiquitously expressed but especially prominent in liver but also lung, brain, platelet, prostate, placenta, and adrenal gland. Diseases associated with... Read More
1998-036 – Histamine N-methyltransferase (HNMT, EC126.96.36.199) catalyzes a major pathway in the metabolism of histamine. The only pathway for the termination of the neurotransmitter actions of histamine in the human CNS is N-methylation catalyzed by HNMT, and approximately 70% of histamine in bronchial epithelium is metabolized by HNMT. Mayo investigators have cloned the cDNA and gene for HNMT in humans and... Read More
1994-072 – The invention provides an isolated and purified human DNA molecule that encodes human estrogen sulfotransferase (EST, SULT1E1). It also provides cell lines and vectors containing human estrogen sulfotransferase DNA that can be used to express the enzyme. The enzyme is useful for screening drugs that are metabolized by human estrogen sulfotransferase.
1993-030 – Human Thiopurine Methyltransferase (TPMT) Gene Discovery - Stably-transformed cells expressing human thiopurine methyltransferase Human Thiopurine Methyltransferase (TPMT) Gene Discovery. Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine, 6-thioguanine and azathioprine. Patent claims to the DNA coding sequence, amino acid sequence and cell lines and mammals in which... Read More